A vaccine to protect humans from a bird flu pandemic is within reach after a new discovery by researchers at the University of Melbourne.
Cellectar, Inc. announced that the FDA has cleared the Company’s Investigational New Drug (IND) application for its 131I-CLR1404 drug candidate.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome.
A new generation of cancer drugs designed to starve tumors of their blood supply – called angiogenesis inhibitors—succeeds at first, but then promotes more invasive cancer growth—sometimes with a higher incidence of metastases, according to a new study in animals.
By altering just one gene in HIV-1, scientists have succeeded in infecting pig-tailed macaque monkeys with a human version of the virus that has, until now, been impossible to study directly in animals.
New findings may significantly improve the safety of methadone, a drug widely used to treat cancer pain and addiction to heroin and other opioid drugs.
A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test.
Lab21 Ltd announced that it has purchased the majority shareholding of Biotec Laboratories Ltd.
Pfizer Inc. announced that it has entered into a series of agreements with Aurobindo Pharma Ltd.
Patheon offers a comprehensive array of contract manufacturing and packaging services from an international network of facilities located throughout Europe and North America.
Xcelience, LLC provides formulation development and clinical supplies manufacturing solutions to virtual, emerging, and large pharmaceutical companies.
UPM has over 12 years experience in solid and liquid dosage formulation development.
SRI International is a leading, independent, nonprofit research institute. Our Biosciences Division is fully integrated “from idea to IND”.
Piramal Healthcare is one of the few CMOs to help develop, scale up, and provide both clinical materials and commercial supply of drug products.
The FDA announced a Consent Decree of permanent injunction filed March 2, 2009, enjoining KV Pharmaceutical Company, its subsidiaries ETHEX Corporation and Ther-Rx Corporation, and its principal officers from making and distributing adulterated and unapproved drugs.